Effects of Local Injection of Different Doses of Anti-RANKL Antibody on Alveolar Bone Osteoporosis in Rats

doi:10.13701/j.cnki.kqyxyj.2024.08.005

Abstract

Abstract: Objective: To explore the effect of local injection of different doses of anti-receptor activator of nuclear factor kappa-B ligand (RANKL) antibody on alveolar bone osteoporosis in rats. Methods: A total of 30 SD rats were selected, with 9 in the control group and 21 in the experimental group. The rat alveolar bone osteoporosis model was established by subcutaneous injection of dexamethasone. The model was verified 5 weeks later. After successful verification, the experimental group was randomly divided into 3 groups. Experimental group Ⅱ and Ⅲ were injected with 0.1 μg/site and 1 μg/site of rabbit anti-rat RANKL antibody in the palatine side of the upper right first molar of rats on day 1, 3, and 7, and experimental group Ⅰ was injected with equal volume of saline. Bone mineral density (BMD) and bone volume fraction (BV/TV) of alveolar bone in the right upper first molar region were measured by micro-CT after 1 week. The changes of histomorphology and the number of osteoclasts were observed by histopathological staining of alveolar bone. Enzyme linked immunosorbent assay (ELISA) was used to detect the RANKL/osteoprotegerin (OPG) ratio in gingival tissue. Results: The rat alveolar bone osteoporosis model was established successfully. Micro-CT and histopathology showed that after antibody injection, alveolar bone BMD and BV/TV were increased, the number of osteoclasts were decreased, osteoblasts were actived, and bone marrow cavity were decreased, but there was no significant change between high and low doses of antibody. ELISA results showed that the ratio of RANKL/OPG in gingival was significantly decreased after high dose antibody injection, however, it was decreased without significance after low dose antibody injection. Conclusion: Local injection of anti-RANKL antibody can improve the alveolar bone osteoporosis in rats, and low dose could reach the improvement effect.

Key words: nuclear factor κB receptor activator ligand inhibitor, anti-receptor activator of nuclear factor-κB ligand antibody, receptor activator of nuclear factor-κB ligand, osteoprotegerin, alveolar bone osteoporosis

ZHOU Jing, ZHANG Jing, WANG Lu, MA Ling, SU Jingyang, ZHANG Zhao. Effects of Local Injection of Different Doses of Anti-RANKL Antibody on Alveolar Bone Osteoporosis in Rats[J]. Journal of Oral Science Research, 2024, 40(8): 687-692.

References

[1] Cheng YT, Liao J, Zhou Q, et al. Zoledronic acid modulates osteoclast apoptosis through activation of the NF-κB signaling pathway in ovariectomized rats [J]. Exp Biol Med (Maywood), 2021, 246(15):1727-1739.
[2] Zhang LL, Zhang ZH, Chen J, et al. Complications related to axial orientation of implants and their research progress [J]. Zhonghua Kou Qiang Yi Xue Za Zhi, 2022, 57(9):969-972.
[3] Zhou Y, Hu Z, Ge M, et al. Intraosseous injection of calcium phosphate polymer-induced liquid precursor increases bone density and improves early implant osseointegration in ovariectomized rats [J]. Int J Nanomedicine, 2021, 16:6217-6229.
[4] Lu W, Zhou Y, Yang H, et al. Efficacy of strontium supplementation on implant osseointegration under osteoporotic conditions: A systematic review [J]. J Prosthet Dent, 2022, 128(3):341-349.
[5] Jonasson G, Skoglund I, Rythén M. The rise and fall of the alveolar process: Dependency of teeth and metabolic aspects [J]. Arch Oral Biol, 2018, 96:195-200.
[6] Kim JE, Man PP, Jang S, et al. Nasal obstruction promotes alveolar bone destruction in the juvenile rat model [J]. J Dent Sci, 2022, 17(1):176-183.
[7] Aibar-Almazán A, Voltes-Martínez A, Castellote-Caballero Y, et al. Current status of the diagnosis and management of osteoporosis [J]. Int J Mol Sci, 2022, 23(16):9465.
[8] Anam AK, Insogna K. Update on osteoporosis screening and management [J]. Med Clin North Am, 2021, 105(6):1117-1134.
[9] Amin N, Boccardi V, Taghizadeh M, et al. Probiotics and bone disorders: the role of RANKL/RANK/OPG pathway [J]. Aging Clin Exp Res, 2020, 32(3):363-371.
[10] Takegahara N, Kim H, Choi Y. RANKL biology [J]. Bone, 2022, 159:116353.
[11] Yasuda H. Discovery of the RANKL/RANK/OPG system [J]. J Bone Miner Metab, 2021, 39(1):2-11.
[12] Chotiyarnwong P, McCloskey E, Eastell R, et al. A pooled analysis of fall incidence from placebo-controlled trials of denosumab [J]. J Bone Miner Res, 2020, 35(6):1014-1021.
[13] Xavier A, Toumi H, Lespessailles E. Animal model for glucocorticoid induced osteoporosis: A systematic review from 2011 to 2021 [J]. Int J Mol Sci, 2021, 23(1):377.
[14] 周静,张钊.骨保护素/核因子κB受体活化因子/核因子κB受体活化因子配体调节骨代谢及其靶向治疗在口腔领域的应用[J].中国组织工程研究,2024,28(23):3736-3742.
[15] Watanabe K, Lewis S, Guo X, et al. Regional variations of jaw bone characteristics in an ovariectomized rat model [J]. J Mech Behav Biomed Mater, 2020, 110:103952.
[16] 王起家,李可大,张江.骨质疏松动物模型研究进展[J].实用中医内科杂志,2023,37(9):134-138.
[17] 李彦冉,闫盼盼,苗艳艳,等.骨质疏松动物模型构建进展与应用特点分析[J].中国实验动物学报,2023,31(7):928-934.
[18] 刘颖,袁晓美,毕亚男,等.补骨脂对维甲酸诱导的大鼠骨质疏松的治疗[J].实验动物科学,2018,35(1):44-47.
[19] Abdul-Fattah Baraka N, Fathallah Ahmed N, Ismail Hussein S. The effect of Rutin hydrate on Glucocorticoids induced osteoporosis in mandibular alveolar bone in Albino rats (Radiological, histological and histochemical study) [J]. Saudi Dent J, 2022, 34(6):464-472.
[20] Lin X, Han X, Kawai T, et al. Antibody to receptor activator of NF-κB ligand ameliorates T cell-mediated periodontal bone resorption [J]. Infect Immun, 2011, 79(2):911-917.
[21] Pan K, Hu Y, Wang Y, et al. RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [J]. Int J Implant Dent, 2020, 6(1):15.
[22] 王璐,周静,张婧,等.RANKL/RANK/OPG通路在口腔相关领域的应用研究[J].口腔颌面修复学杂志,2023,24(4):313-320.
[23] Lin J, Bi L, Yu X, et al. Porphyromonas gingivalis exacerbates ligature-induced, RANKL-dependent alveolar bone resorption via differential regulation of Toll-like receptor 2 (TLR2) and TLR4 [J]. Infect Immun, 2014, 82(10):4127-4134.